Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer

Experimental and Molecular Pathology

Volumn 97, Issue 3, 2014, Pages 579-584

  Xu, Xin ^a,f   Tang, Xiaojun ^a,f   Lu, Meiping ^a   Tang, Qi ^a,f   Zhang, Huilin ^b   Zhu, Huijun ^a   Xu, Ning ^a,f   Zhang, Dawei ^c   Xiong, Lin ^d   Mao, Yuan ^d   Zhu, Jin ^a,e,f  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

^d THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e Jiangsu Provincial Hospital   (China)

^f Huadong Medical Institute of Biotechniques   (China)

Author keywords

IDC; Immunohistochemistry; MAGE A9; Prognosis; QPCR; Tissue microarray

Indexed keywords

MELANOMA ANTIGEN; MELANOMA ASSOCIATED ANTIGEN A9; UNCLASSIFIED DRUG; MAGEA9 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA ASSOCIATED ANTIGEN A9 GENE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; VERY ELDERLY; BIOSYNTHESIS; BREAST TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84910651722     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.11.001     Document Type: Article

References (28)

1. Abernethy A.P., Shelby-James T., Fazekas B.S., et al. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat. Care 2005, 4:7.
2. Bergeron A., Picard V., LaRue H., et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int. J. Cancer 2009, 125:1365-1371.
3. Cameron B.J., Gerry A.B., Dukes J., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 2013, 5:197-103.
4. Chen W.Q., Zheng R.S., Zhang S.W., et al. Report of incidence and mortality in China cancer registries. Chin. J. Cancer Res. 2008, 24:171-180.
5. Corbiere V., Chapiro J., Stroobant V., et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011, 71:1253-1262.
6. Coughlin S.S., Ekwueme D.U. Breast cancer as a global health concern. Cancer Epidemiol. 2009, 33:315-318.
7. Fu M., Fan W., Pu X., et al. Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2013, 6:2185-2191.
8. Hamaï A., Memeo L., Colarossi C., et al. Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers. Ann. Oncol. 2011, 2011:986-987.
9. Hatiboglu G., Pritsch M., Macher-Goeppinger S., et al. Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. Scand. J. Urol. 2013, 47:311-322.
10. Huang J., Zhang J., Li H., et al. VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am. J. Transl. Res. 2013, 5:336-346.
11. Krauss E., Rauthe S., Gattenlöhner S., et al. MAGE-A antigens in lesions of the oral mucosa. Clin. Oral Investig. 2011, 15:315-320.
12. Lin H., Huang J.F., Qiu J.R., et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp. Mol. Pathol. 2013, 94:73-78.
13. Lin H., Mao Y., Zhang D.W., et al. Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin. Anticancer Agents Med. Chem. 2013, 13:1259-1266.
14. Lin H., Zhang H., Wang J., et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int. J. Cancer 2014, 134:1239-1249.
15. Ma J., Wang J., Fan W., et al. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7:246-254.
16. Marx A.H., Zielinski M., Kowitz C.M., et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology 2010, 57:418-426.
17. Meek D.W., Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 2012, 324:126-132.
18. Monte M., Simonatto M., Peche L.Y., et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11160-11165.
19. Nardiello T., Jungbluth A.A., Mei A., et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin. Cancer Res. 2011, 17:4309-4319.
20. Oehlrich N., Devitt G., Linnebacher M., et al. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int. J. Cancer 2005, 117:256-264.
21. Paudyal B., Zhang K., Chen C.P., et al. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nucl. Med. Biol. 2013, 40:994-999.
22. Péus D., Newcomb N., Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med. Inform. Decis. Mak. 2013, 13:72.
23. Picard V., Bergeron A., Larue H., Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int. J. Cancer 2007, 120:2170-2177.
24. Straetemans T., van Brakel M., van Steenbergen S., et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin. Dev. Immunol. 2012, 2012:586314.
25. Taneja P., Maglic D., Kai F., et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin. Med. Insights Oncol. 2010, 4:15-34.
26. Vantomme V., Dantinne C., Amrani N., et al. Immunologic analysis of a phase MAGE A9 I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 2004, 27:124-135.
27. Xiang D., Liu C.C., Wang M.J., et al. Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation. Cell Death Dis. 2014, 5:e1252.
28. Zhu H., Lu J., Wang X., et al. Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor. Med. Oncol. 2013, 30:631.